BioStock: Prolight Diagnostics’ CEO comments on the outcome of the rights issue
Prolight Diagnostics recently announced the outcome of its rights issue, which will finance the continued development of the company's point-of-care system. The share issue was subscribed to approximately 24 per cent. Approximately 76 per cent of the issue was covered by subscription commitments, bottom underwriting commitments and top-down underwriting commitments. The bottom guarantors were allotted approximately 31 per cent and the top-down guarantors 21 per cent, resulting in influx of around 75.2 MSEK for the company. BioStock reached out CEO Ulf Bladin to get to know about the allocation of this capital.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se
